Dyadic International, Inc.
DYAI
NASDAQ·Healthcare·Biotechnology·Mkt cap $22.4M
$0.61
▼ -3.91%
P/E
-2.88
Mkt Cap
$22.4M
52-Wk Range
$0.60–$1.60
52-Week Range
$0.60 - $1.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 33.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary C1 platform technology for efficient protein production
- Cost-effective manufacturing capabilities for complex biologics
- Strategic partnerships with leading biotech and research institutions
- Established expertise in vaccine and therapeutic protein development
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Clinical development of DYAI-100 COVID-19 vaccine candidate
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-24.0% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DYAI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.06 vs -$0.04 consensus (-71.4% surprise). Revenue of $961.1K vs $1.0M expected (-6.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-71.4%
Revenue trend · last 8Q
—
—
-45%
+20%
-41%
+56%
+507%
+107%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.0M
$817.4K
$183.1K
$463.4K
$1.2M
$1.3M
$1.1M
$961.1K
Margins · last 8Q
Gross
87.2%
Operating
—
Profit
-221.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How DYAI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related